Cargando…
Infliximab Preferentially Induces Clinical Remission and Mucosal Healing in Short Course Crohn's Disease with Luminal Lesions through Balancing Abnormal Immune Response in Gut Mucosa
This study was undertaken to evaluate the efficacy of infliximab (IFX) in treatment of Crohn's disease (CD) patients. 106 CD patients were undergoing treatment with IFX from five hospitals in Shanghai, China. Clinical remission to IFX induction therapy was defined as Crohn's disease activi...
Autores principales: | Yu, Lijuan, Yang, Xuehua, Xia, Lu, Zhong, Jie, Ge, Wensong, Wu, Jianxin, Liu, Hongchun, Liu, Fei, Liu, Zhanju |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Hindawi Publishing Corporation
2015
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4383520/ https://www.ncbi.nlm.nih.gov/pubmed/25873771 http://dx.doi.org/10.1155/2015/793764 |
Ejemplares similares
-
Infliximab for medical induction of remission in Crohn's disease
por: Gordon, Morris, et al.
Publicado: (2023) -
Prognostic factors for the efficacy of infliximab in patients with luminal fistulizing Crohn’s disease
por: Ma, Ye, et al.
Publicado: (2023) -
Efficacy of infliximab treatment on the mucosal healing of different intestinal segments in patients with ileocolonic Crohn’s disease
por: Wu, Yaling, et al.
Publicado: (2020) -
Mucosal Healing Did Not Predict Sustained Clinical Remission in Patients with IBD after Discontinuation of One-Year Infliximab Therapy
por: Dai, Cong, et al.
Publicado: (2014) -
Trough level of infliximab is useful for assessing mucosal healing in Crohn's disease: a prospective cohort study
por: Koga, Akihiro, et al.
Publicado: (2018)